HealthFlex
×
  • Home
  • For Patients
    • What is an ERN?
    • Understand your Diagnosis
    • News for Patients
    • Meetings & Events
    • Support Groups
      • Find a Health Care Professional
      • Contact
    • Cross-border Healthcare
  • Our Network
  • ERN Expertise
    • Rare Diseases Subnetworks
    • Transversal Activities
    • Work Packages
    • Patient Board
  • Media
    • Informative Materials
  • What's New
    • News
    • News for Patients
    • Meetings & Conferences
    • Newsletter
  • ERNs
  • Links
  • Contact
  • Privacy Policy

NORD Launches RareInsights – 5 Myths About Orphan Drugs

NORD Launches RareInsights – 5 Myths About Orphan Drugs
NewsNews for Patients

Washington, D.C., May 30, 2018—The National Organization for Rare Disorders (NORD) today launched RareInsights™, its new initiative to expand public knowledge of rare diseases and translate that knowledge into real-world solutions for patients and families, and kicked off the program with the  infographic 5 Myths About Orphan Drugs and the Orphan Drug Act.

“At NORD, we believe that it is critical for next generation advocacy to include empirical data in order to affect change,” said Pamela Gavin, Chief Strategy Officer for NORD. “RareInsights is the program through which NORD will release data-driven insights that support rare disease advocacy priorities. It will feature presentations of data-based information in a variety of accessible formats, including white papers, infographics, fact sheets, and more.”

The first offering from RareInsights, 5 Myths About Orphan Drugs and the Orphan Drug Act, is an infographic that addresses some of the most common misperceptions as identified in a recent study commissioned by NORD and published by the QuintilesIMS Institute (now IVQIA). The study analyzed the role of the Orphan Drug Act and orphan drug usage and costs in the context of public policy and health care financing issues in the rare disease community.

The 5 Myths touch on hot button topics including the limited role that orphan drug costs contribute to overall health care costs, distinguishing between specialty vs orphan drugs, and the benefits of the Orphan Drug Act.

According to NORD President and CEO Peter L. Saltonstall, there are many misconceptions about orphan drug costs and about the benefits of the Orphan Drug Act.  “The QuintilesIMS study provided data reinforcing the basic value of the Orphan Drug Act and quantifying orphan drug spending within the broader context of total drug sales. Simply put, orphan drug spending is not as substantial as has been reported. As NORD marks its 35th anniversary and the 35th year of the Orphan Drug Act, we look forward to continuing to provide the voice of the rare disease patient community and playing a vital role in these discussions,” he said.

About 7,000 rare diseases have been identified, affecting 25 to 30 million Americans. Of the 7,000 that exist, fewer than 500 rare diseases have FDA-approved treatments. Many affect only a few hundred or a few thousand individuals. Rare diseases tend to be chronic, serious and life-threatening.  More than 80% are believed to be genetic. The Orphan Drug Act is a catalyst for incentivizing interest in developing treatments for rare diseases and is critical for continuing to close the gap for the 95% of patients who are still without any approved treatment options.

5 Myths About Orphan DrugsEditor’s note:  Peter L. Saltonstall, President and CEO of NORD, is available for interviews on RareInsights and the 5 Myths About Orphan Drugs and the Orphan Drug Act.  Contact Laura Mullen at lmullen@rarediseases.org.

Source: https://rarediseases.org

Search

  • News
  • Meetings & Conferences
  • EU Calls
  • Newsletter

Next events

No Events scheduled

more info

Latest news

  • Rare Disease Day Verona | Weekend Programme
  • Rare Disease Day Freiburg | Webinar | 26 February 2021
  • Information Webinar | February 2nd, 2021
  • innovation projects in clinical trials methodologies
  • EJPRD Policy Meeting | 12 – 13 January 2021

Archives

Metabern Newletter

logo

For more information please contact
Prof. Maurizio Scarpa, MD, PhD
MetabERN Coordinator

MetabERN is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission. For more information about the ERNs and the EU health strategy, please visit ec.europa.eu/health/ern

Follow us on Twitter

Tweets by @Metab_ERN

MetabERN

  • Home
  • For Patients
    • What is an ERN?
    • Understand your Diagnosis
    • News for Patients
    • Meetings & Events
    • Support Groups
      • Find a Health Care Professional
      • Contact
    • Cross-border Healthcare
  • Our Network
  • ERN Expertise
    • Rare Diseases Subnetworks
    • Transversal Activities
    • Work Packages
    • Patient Board
  • Media
    • Informative Materials
  • What’s New
    • News
    • News for Patients
    • Meetings & Conferences
    • Newsletter
  • ERNs
  • Links
  • Contact
  • Privacy Policy

Copyright ©2017-2019 all rights reserved
Web by EFFIGE 2.0
To provide the best possible service, we use technical, statistical and third-party cookies on this site. Continuing the navigation you consent to use them. Accept Reject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.